• 대한한의학원전학회지
• /
• 제19권4호
• /
• pp.219-225
• /
• 2006

The result is the followings after investigating composition, dosage and usage of Sagunjatang(四君子湯), Samultang(四物湯), Palmultang(八物湯), Sipjeondaebotang(十全大補湯) in literature by country and Era 1. Sagunjatang has become equal to Panax ginseng(人蔘), Atractylodes japonica(白朮), Poria cocos(복령) each for 2 Jeon(錢), Glycyrrhiza uralensis(甘草) 1 jeon since the Ming Dynasty in China and it is standardized by Panax ginseng, Atractylodes japonica, Poria cocos and Glycyrrhiza uralensis each for 1 Jeon 2 Pun(分) 5 Ri(里) since Dongeuibogam in Korea. 2. Samultang has become equal to Angelica gigas(當歸) and Rehmannia glutinosa(地黃) each three Jeon, Cnidium officinale(川芎) is 1 Jeon 2 Pun or 1 jeon and Paeonia lactiflora(芎藥) 2 Jeon since the Ming Dynasty in China and it is standardized by Angelica gigas, Cnidium officinale, Paeonia lactiflora and Rehmannia glutinosa each for 1 Jeon 2 Pun 5 Ri since Dongeuibogam in Korea. 3. In the case of Palmultang, compositional usage of medicine was different in the Ming Dynastry and the Ching(靑) Dynastry in China. Total dosage was increased and ratio of Angelica gigas and Rehmannia glutinosa was increased comparatively in the Ching Dynasty. All prescription of medicine was consisted of 1 Jeon 2 Pun and specific dosage was presented except Euirimchwalyo(醫林撮要) that dosage was not recorded in Korea. 4. Sipjeondaebotang tended to increase total dosage in the latter part in China. Dosage was mostly used 1 Jeon thus Dongeuibogam but Bangyakhap(方藥合編) used 1 Jeon 5 Pun differentially.

• 대한약침학회지
• /
• 제12권4호
• /
• pp.5-32
• /
• 2009

Objectives: This study was performed to analyse single dose toxicity of pure melittin(Sweet Bee Venom-Sweet BV) extracted from the bee venom by utilizing protein isolation method of gel filtration. Methods: All experiments were conducted at Biotoxtech, a non-clinical studies authorized institution, under the regulations of Good Laboratory Practice (GLP). Six weeks old female Sprague-Dawley rats were chosen for the pilot study and determined 30㎎/㎏ which is 4285 times higher than the clinical application dosage as the high dosage, followed by 15 and 7.5㎎/㎏ as mid and lose dosage, respectively. Equal amount of excipient to the Sweet BV experiment groups was administered as the control group. Results: 1. No mortality was witnessed in all of the experiment groups. 2. Hyperemia and movement disorder were observed around the area of administration in all groups, and higher occurrence in the higher dosage groups. Hyperemia and movement disorder diminished with elapsed time. 3. For the weight measurement, male groups showed larger reduction in weight in accordance with higher dosage. Female groups didn't s how significant changes. 4. To verify abnormalities of organs and tissues, cerebellum, cerebrum, liver, lung, kidney, and spinal nerves were removed and conducted histological observation with H-E staining. No abnormalities were detected in any of organs and tissues. 5. One female rat in the 30㎎/㎏ group had amputated toe near the administered area and histopathological finding was hemorrhage with inflammation. This is presumed as a secondary infection after the administration of Sweet BV. Conclusion: Above findings suggest Sweet BV is relatively s safe treatment medium. Further studies on the subject should be conducted to yield more concrete evidences.

• 대한약침학회지
• /
• 제13권3호
• /
• pp.15-46
• /
• 2010

Objectives: This study was performed to analyse the effects of Sweet Bee Venom(Sweet BV) on cardiovascular system in the conscious telemetered Beagle Dogs. Methods: All experiments were conducted at Biotoxtech Company, a non-clinical studies authorized institution, under the regulations of Good Laboratory Practice (GLP). Male Beagle dogs of 13-19 months old were chosen for the pilot study and surgical implantation was performed for conscious telemetered Beagle dogs. And after confirming condition of Beagle dogs was stable, Sweet BV was administered 4 times(first: 0.0 mg/kg, 2nd: 0.01 mg/kg, 3rd: 0.1 mg/kg, and forth: 0.5 mg/kg, one time/week) in thigh muscle of Beagle dogs. And blood pressure, heart rate, electrocardiography and clinical responses were measured. Equal amount of normal saline to the Sweet BV experiment groups was administered to the control group. Results: 1. In the analysis of body weight and taking amount, Beagle dogs did not show significant changes. 2. In the clinical observation, responses of pain and edema were showed depend on dosage of Sweet BV. 3. In the analysis of blood pressure, treatment with Sweet BV did not show significant changes in the dosage of 0.01 mg/kg, but in the dosage of 0.1 mg/kg and 0.5 mg/kg, treatment with Sweet BV increased blood pressure significantly. 4. In the analysis of heart rate, treatment of Sweet BV did not show significant changes in all dosage and period. 5. In the analysis of electrocardiography, treatment of Sweet BV was not showed significant changes in all dosage and period. Conclusion: Above findings suggest that Sweet BV is relatively safe treatment in the cardiovascular system. But in the using of over dosage, Sweet BV may the cause of increasing blood pressure. Further studies on the subject should be conducted to yield more concrete evidences.

• 한국의료질향상학회지
• /
• 제9권2호
• /
• pp.230-240
• /
• 2002

Background : The purpose of this study was to develop, implement and evaluate the pharmacist intervention program designed to identify and correctly adjust the dosage of $H_2$-receptor antagonists ($H_2RA$) in renally impaired patients and promote timely conversion of $H_2RA$ from IV to PO therapy. Methods : The study population consisted of renally impaired patients who received $H_2RA$ therapy from April 9 to May 8, 2001 at Hallym Medical Center. Each morning a specifically developed software program identified patients with serum creatinine (Scr) greater than 1.2 mg/dl or age greater than 65 years. The pharmacist, then screened the pharmacy profiles of the identified patients to determine if the patient was on $H_2RA$. For these patients on $H_2RA$ with renal impairement the creatinine clearance (CrCl) was calculated using Cockroft & Gault equation. The pharmacist determined the proper dosage for each identified patients based on the calculated CrCl and the oral dosage that would be appropriate for whom IV therapy was no longer indicated. Result : A total of 149 cases (101 patients) were monitored during the study period. The dosage was inappropriately prescribed for renal function in 61 of 149 cases (41%), and of those, pharmacist made recommendations for 58 cases of which 33 cases (57%) were accepted by the physicians. The administration route of H2RA was inappropriately used as IV in 22 of 53 cases (42%), and pharmacist made recommendations for those 22 cases of which 15 cases (68%) were accepted. Conclusion : Monitoring of patients with renal dysfunction by a pharmacist improved the dosing of $H_2RA$ and a dosing program of patients with renal impairment would be of benefit to other clinicians and institutions seeking to optimize patient care.

• 한국환경과학회지
• /
• 제8권5호
• /
• pp.625-631
• /
• 1999

This study was performed to determine the optimum coagulant dosing for effective treatment of raw water in Chinyang lake. Removal rates of algae and characteristics of the water according to coagulants dosage were investigated by treatment with Microcystis aeruginosa, which is a kind of blue-green algae, to the raw water below 5NTU. The coagulants dosage for maximum removal rate of algae were 30 mg/$\ell$ of Alum, 30 mg/$\ell$ of PAC and 10 mg/$\ell$ of PACS, respectively. The removal rate of algae in 30 mg/$\ell$ of PAC was highest as 85% compared with the other treatments. At the point of maximum removal rate of algae, the removal rates of turbidity were 34%, 66% and 22% in Alum, PAC and PACS, respectively. Residual Al was decreased depend upon decreasing turtidity in water by treatment of Alum or PAC, but decreased depend upon increasing turbidity in water by treatment of PACS. The removal rate of ${Mn}_{2+}$ in water was high in the order of Alum, PAC and PACS treatment. And ${Fe}_{2+}$ in water was not changed by treatemnt of these coagulants. Particle numbers distributions according to the particle size of suspended solids that were not precipitated at 8 min. of settling time after treatment of coagulants dosage for the maximum removal rate of algae were investigated. Most of the particle sizes were below 30 $\mu$m and particle numbers distributions below 10 $\mu$m were 64%, 56% and 66% by treatment of Alum, PAC and PACS, respectively. Zeta potential was in the range of -6.1~-9.7 mV at optimum coagulants dosage for algae removal.

• 대한한의학방제학회지
• /
• 제13권1호
• /
• pp.123-143
• /
• 2005

Objective : This study was carried out to evaluate the liver toxicities of Wild Aconiti Tuber decoction. Methods : The amounts of aconitine in the methanol extract of Wild Aconiti Tuber was measured by HPLC. Safeties was studied by LD50 in mice. Liver toxicities were evaluated histologically and by CBC, blood chemistry after 2 weeks of 0.4g/kg/day clinical dosage oral administrations in rat. Results : 1. The amounts of aconitine in the methanol extract of Wild Aconiti Tuber is $1.697{\pm}0.052mg/g$. But aconitine was not detected in the water decoction of Wild Aconiti Tuber. 2. To evaluate LD50 and safeties of Wild Aconiti Tuber decoction, ICR mice were given high dose of 2, 5, 10g/kg for single time and were observed for 2 weeks. There were no dead animal and abnormal clinical sign and no abnormalities at the autopsy. So, LD50 was admitted to higher than 10g/kg. 3. After 2 weeks of 0.4g/kg/day clinical dosage oral administrations in rat, there was no significant change in the CBC and blood chemistry. 4. In the liver tissues of clinical dosage, mitotic figures, apoptosis and individual cell death were observed, but clear liver toxicities like fatty liver or necrosis were not observed. the liver tissues of high dose in mice, hydropic changes were getting severe as dose grows. Conclusions : According to the results, though aconitine was not detected in the Wild Aconiti Tuber decoction, 0.4g/kg/day 2 weeks p. o (clinical dosage) group showed weak changes in the liver tissues and high dose group showed liver toxicities like hydropic changes.

• The Korean Journal of Physiology
• /
• 제16권2호
• /
• pp.177-186
• /
• 1982

The effect of ethacrynic acid (EA) on the renal secretion of PAH was examined in cat kidney. $C_{PAH}$ and $T_{PAH}$ were measured before and after infusion of EA $(0.5{\sim}50mg/kg)$ through the femoral vein. The following results were obtained: 1) In the dosage range of 0.5 to 25 mg/kg, EA increased the urine flow, and sodium and potassium excretion in dose-dependent manner, but the glomelular filtration rate was decreased as the dosage of EA was increased. 2) $C_{PAH}$ and $T_{PAH}$ were decreased by EA in the dosage range of 3 to 25 mg/kg and 1 to 50 mg/kg, respectively, in dose·dependent manner with the dosage to cause 50% inhibition of about 5 mg/kg. 3) With dosage of 0.5mg/kg, EA appeared to exert a great effect on diuretic response without the influence on $T_{PAH}$. At 10min after infusion of EA, a potent diuretic effect appeared, while $T_{PAH}$ did not show a significant change. These results suggest that the action mechanism of EA on tubular secretion of PAH may be different from that on natriuresis. 4) With dosage of 5 mg/kg, EA did not inhibit the Na-K-ATPase activity in microsomal fractions from both cortex and medulla. 5) The double reciprocal plot ($l/T_{PAH}$ versus $l/P_{PAH}$) suggested that EA inhibited the P AH secretion by a competitive pattern. However, probenecid, a prototypic inhibitor of the organic acid pump, had no influence on both the inhibitory effect of $T_{PAH}$ and the natriuretic effect by EA. These results suggest that in vivo EA altered tubular secretion of P AH through interactions with receptors that are not identical with the Na-K-ATPase.

• 한국임상약학회지
• /
• 제22권3호
• /
• pp.220-227
• /
• 2012

Kidney and liver are the major organs of metabolism and excretion of drugs. Renal and Hepatic impairment may affect the pharmacokinetics/pharmacodynamics and the safety of drugs. Adjusting the dosage based on organ function is the essential role of pharmacists. However, differences have been noted on the recommended dosage among the literatures. We compared and analyzed the recommendations of 4 literature sources which are commonly used for dosage adjustment. From April, 2011 to August, 2011, we selected data on recommendations for dosage adjustment for impaired renal and hepatic function of 100 drugs through a protocol. We analyzed the definition terms of renal and hepatic impairment, recommendations for dosage adjustment, evidenced references in four literature sources: Korean National Formulary (KNF), American Hospital Formulary System Drug Information (AHFS), Micromedex (MM) and Drug Prescribing of Renal Failure (DPRF). We further examined the data homogeneity by comparing how drugs that required no adjustment according to one source were categorized by the other. Sources use different definition terms among themselves except DRPF. Presence or absence of evidenced references about renal/hepatic functional states are KNF (0%/0%), AHFS (78%/62.6%), MM (87.5%/65.6%) and DPRF (93.2%/no recommendation) respectively. Recommendations of specific dosage and dosing interval are KNF (24%/13%), AHFS (39.6%/12.1%), MM (50%/17.7%), and DPRF (55.4%/no recommendation) respectively. Regarding the data homogeneity, the differences were remarkable. Drugs with no adjustment according to AHFS were categorized to be adjusted/ contraindicated by KNF, MM, DPRF and the values were (44%/5.6%), (22%/0%), and (36%/0%) in renal function, (39%/6.5%), (19%/3.2%), and (no recommendation/no recommendation) in hepatic function respectively. Our study shows remarkable definite variation in definitions and recommendations about definition terms, information of dosage and interval, presence or absence of evidenced references. Especially for KNF, quantitative recommendations on dosages and dosing intervals should be made in the near future. To maximize the drug effect and safety and to minimize the heterogeneity of the literature sources, reviewing at least two sources are suggested when recommending the proper dosage adjustment based on organ function.

• 대한기계학회논문집B
• /
• 제26권6호
• /
• pp.757-764
• /
• 2002

Chlorination dosage in water treatment plant of field is determined by chlorination demand experiment through two or three hours after raw water was sampled in inflow. It is impossible to continuously control for real time because the sampled water is adapted chlorination dosage after water treatment process had been proceeded. Therefore in this study, we will design informal chlorination demand system, this designed system will be experimented as to water quality and accuracy of control in various conditions. Throughout these experimental results, we will revise the system and the revised system is enable to optimal control of chlorination dosage. Finally, we have developed chlorination demand system, which can automatically determination of chlorination dosage to be determined according to variety of raw water quality inflow in water treatment plant.

• Journal of Pharmaceutical Investigation
• /
• 제19권4호
• /
• pp.191-194
• /
• 1989

Bioequivalence test of $Asthcontin^{\circledR}$ tablet, a commercial slow-release theophylline (TP) dosage form, was performed using $Slo-bid^{\circledR}$ capsule as the reference. Since it has been confirmed that the saliva concentration of TP is closely correlated with the plasma concentration in man, the area under the saliva concentration-time curve was used as a bioavailability parameter. The statistical analysis showed that the two dosage forms are equivalent in bioavailability estimating from the saliva concentration. The results supported that the use of soliva as a test sample provides simple and easy techniques for bioequivalence tests of TP-containing dosage forms.